RxDoctor Payments Data

Martin Thomley, MD

Retina Specialist · Hattiesburg, MSNPI 1679558357

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,629 of the $2,103 with a category attached, or 77.5%. 7 manufacturers reported payments, led by Alcon at 58.9% of the total. Reporting peaked in 2020 at $887 and has fallen 77.4% since, to $200 in 2025.

$2,103in general payments, 2019–2025

Across 31 payments — averaging $67.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • US Retina LLC$474
  • AbbVie$215
  • Carl Zeiss Meditec, Inc.$70
  • Astellas Pharma US Inc$58
  • Mallinckrodt Hospital Products Inc.$35
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$1,62977%
  • Ownership interest$47423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,477,074
Medicare patients
1,117
Services billed
57,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate272$8,461
CombiganBrimonidine Tartrate/Timolol27$5,582
SimbrinzaBrinzolamide/Brimonidine Tart16$3,127
Alphagan PBrimonidine Tartrate13$2,315
Atropine Sulfate46$2,068
Ofloxacin121$1,345
Ketorolac Tromethamine37$1,187
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$930
Brimonidine Tartrate31$677
Latanoprost77$573
Timolol Maleate17$70
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Alphagan P$215$7,89740 claims
AlconSimbrinza$1,239$3,12716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other retina specialist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →